Graph AI Raises $13.3M Series A Led by Insight Partners

Graph AI Closes $13.3M Series A

Graph AI, a California-based AI life sciences startup, has raised $13.3 million in Series A funding. The round was led by Insight Partners, with participation from Bessemer Venture Partners. The funding was announced on September 10, 2026.

What Graph AI Does

Founded in 2024, Graph AI develops AI-driven pharmacovigilance solutions to automate drug safety monitoring and improve patient safety. Its flagship product, Graph Safety Suite, is a SaaS platform that integrates fragmented workflows in pharmacovigilance. The platform automates adverse drug event detection, case processing, signal detection, regulatory reporting, and compliance to enhance efficiency and accuracy for pharmaceutical companies.

Funding Details

• Round: Series A
• Amount: $13,300,000 USD
• Announced: September 10, 2026
• Lead Investor: Insight Partners
• Participating Investors: Bessemer Venture Partners

Acquisition Perspective

The Series A provides Graph AI with capital to advance its AI-driven pharmacovigilance platform and expand its reach within the pharmaceutical industry. Pharmacovigilance is a critical, regulation-heavy function where automation can drive significant efficiency gains and reduce compliance risks. Graph AI's SaaS model and focus on integrating fragmented workflows position it as a potential acquisition target for larger healthcare IT, life sciences software, or regulatory compliance platforms seeking to add AI-powered drug safety capabilities.

The backing of Insight Partners and Bessemer Venture Partners adds credibility and strategic support as Graph AI scales. As the company grows its customer base among pharmaceutical companies, its technology and market traction will be key indicators for future acquisition interest.